Study Evaluating the Safety, Tolerability, and Efficacy of Xaluritamig in Combination With Androgen Receptor Pathway Inhibitors in Participants With Metastatic Hormone-sensitive Prostate Cancer
NCT07140900
This study is recruiting at 8 US sites in 7 states, according to its ClinicalTrials.gov record last updated .
Summary
The main objective of the trial is to evaluate the safety and tolerability of xaluritamig in combination with darolutamide or abiraterone.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 1
- Ages
- 18 years and older
- Sex
- Male
- Healthy volunteers
- Not accepted
- Sponsor
- Amgen
- Last updated on ClinicalTrials.gov
- July 2, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
California · 1
- University of California San Francisco · San Francisco, CA
Massachusetts · 1
- Dana Farber Cancer Institute · Boston, MA
Minnesota · 1
- University of Minnesota · Minneapolis, MN
Ohio · 1
- Cleveland Clinic Foundation · Cleveland, OH
Pennsylvania · 2
- Thomas Jefferson University · Philadelphia, PA
- University of Pittsburgh Medical Center Hillman Cancer Center · Pittsburgh, PA
South Carolina · 1
- South Texas Accelerated Research Therapeutics - Carolinas · Myrtle Beach, SC
Tennessee · 1
- Sarah Cannon Research Institute · Nashville, TN
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.